GMP Fundamentals: The 6 Systems Every FDA Inspector Checks First

When an investigator arrives at a drug manufacturing site, they do not read your procedures at random. They work to a structured model. Understanding that model is one of the GMP fundamentals that separates sites that walk into an inspection with confidence from sites that find out, in real time, where their gaps are. The FDA groups drug manufacturing operations into six systems, and its investigators are trained to evaluate each one and the links between them.

GMP fundamentals and the six-system inspection model

The six-system approach comes from the FDA's drug manufacturing inspection program, which directs investigators to assess the Quality System plus five manufacturing systems. An inspection can be a full evaluation of all six or a focused look at a subset, but the Quality System is almost always in scope because it holds the others together. Knowing what sits inside each system, and what tends to get cited, lets you prepare in a way that mirrors how you will actually be assessed.

This piece walks through the six systems in the order they usually matter, what an investigator looks for in each, and the questions worth asking yourself before someone else asks them.

The Quality System: the one that is always in scope

The Quality System is the overarching system and the reason a systems-based inspection rarely skips it. It covers your quality unit's independence and authority, how you handle deviations and investigations, change control, complaints, product quality reviews, and the management oversight that ties them together. When an investigator wants to know whether a problem is isolated or systemic, this is where they look.

The most common weakness is not the absence of procedures. It is investigations that do not reach a true root cause, corrective actions that do not prevent recurrence, and trends that are visible in the data but never escalated. If your deviation system closes records on time but the same issue keeps returning, an investigator will see it. Strengthening this system is often the highest-leverage work a site can do, because it is what an inspector uses to judge every other system.

Facilities and Equipment: where contamination control lives

This system covers buildings, utilities, equipment design, cleaning, maintenance, and calibration. For sterile and non-sterile sites alike, it is where much of contamination control is won or lost. Investigators look at whether the facility layout supports the process, whether equipment is qualified and maintained, and whether cleaning is validated and consistently performed.

Design decisions made years earlier show up here. Poor flows, hard-to-clean equipment, and utilities that were never sized for current demand all become inspection findings. A structured approach such as Contamination Control by Design treats these as deliberate choices rather than problems to remediate later. Where a site has already inherited weak infrastructure, GMP remediation focuses on closing the highest-risk gaps first.

Materials System: control from receipt to release

The Materials System covers how you receive, sample, test, store, and control components, containers, closures, and finished product, along with supplier qualification and inventory control. Investigators check whether materials are quarantined and released correctly, whether sampling is representative, and whether your supplier oversight is real rather than paper-based.

Weak points cluster around supplier qualification that never revisits performance, and material controls that depend on a single person's knowledge rather than a defined system. If a raw material problem reaches your process, this is the system that should have caught it.

Production System: does the process do what you validated

This system covers process validation, batch records, in-process controls, and the day-to-day execution of manufacturing. Investigators look at whether the validated state is maintained, whether operators follow the record as written, and whether in-process limits are meaningful and acted on.

The recurring theme is drift. A process that was validated three years ago may now run with small, undocumented adjustments that nobody captured through change control. Continued process verification is what should surface that drift before an inspector does.

Packaging and Labeling: small errors, large consequences

Packaging and labeling covers reconciliation, line clearance, label control, and the checks that prevent mix-ups. It is a smaller system by scope but a high-consequence one, because a labeling error can trigger a recall. Investigators focus on line clearance discipline and label accountability.

Laboratory Control System: the integrity of your data

The Laboratory Control System covers your testing, methods, stability program, out-of-specification handling, and, increasingly, data integrity. This is where many enforcement actions concentrate, because laboratory data is the evidence that a product meets its specification. Investigators look at whether methods are validated, whether out-of-specification results are investigated properly, and whether the underlying data is complete, attributable, and secure.

Data integrity findings in the laboratory frequently trace back to the Quality System, which is why the two are so often cited together. A site preparing for inspection should treat regulatory readiness across these systems as one exercise rather than six separate ones.

How the systems connect

The reason the model works for investigators is that the systems are not independent. A materials problem becomes a production problem, a production deviation becomes a Quality System investigation, and a laboratory result becomes the evidence for release. Preparing system by system in isolation misses the linkages that an experienced investigator follows. A GMP audit-ready review looks at those connections deliberately, because that is how a real inspection unfolds.

Frequently asked questions

What are the six systems in an FDA drug manufacturing inspection?

They are the Quality System, the Facilities and Equipment System, the Materials System, the Production System, the Packaging and Labeling System, and the Laboratory Control System. The Quality System is the overarching one and is almost always evaluated.

Which system is inspected first?

The Quality System is nearly always in scope because it governs the others. An investigator may then focus on one or more of the five manufacturing systems depending on the inspection type and the site's history.

Do all inspections cover all six systems?

No. A full inspection evaluates the Quality System plus at least four others, while an abbreviated inspection may cover the Quality System plus one more. The Quality System is the constant.

How do I prepare for a systems-based inspection?

Prepare the way you will be assessed. Review each system for the findings it typically attracts, then check the connections between systems, since investigators follow a problem across system boundaries rather than treating each in isolation.

Kieran Falvey is Founder and Managing Director of Pharmalliance Consulting Ltd and the creator of Contamination Control by Design (CCbD). He has more than 20 years designing, building and running pharmaceutical facilities worldwide, across FDA, EMA, TGA, PIC/S and Indian FDA (CDSCO) jurisdictions. Global expert in cGMP Compliance, Remediation and Contamination Control, helping Sterile, Non-Sterile, ATMP and Cosmetic companies navigate cGMP compliance issues.

Pharmalliance Consulting is a GMP compliance consultancy serving pharmaceutical, sterile, non-sterile, OSD, ATMP and cosmetic manufacturers in Ireland, the UK, the EU and the US. It helps sites identify and remediate GMP risks across facilities, quality systems and contamination control, aligned with HPRA, MHRA, EMA and FDA expectations, turning findings into defensible, inspection-ready practice.

If you want to know how each of these six systems would hold up under inspection, Pharmalliance can help you find out before an investigator does. Talk to us about a GMP audit-ready review or contact the team.